Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants

Current European and US guidelines for recombinant hepatitis B vaccine (rHBV) after hematopoietic-cell transplantation (HCT) vary. The European Group for Blood and Marrow Transplantation (EBMT) recommends rHBV starting 6 to 12 months after HCT. Immunization is optional in the Centers for Disease Con...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Jaffe, Dana, Papadopoulos, Esperanza B., Young, James W., O'Reilly, Richard J., Prockop, Susan, Kernan, Nancy A., Jakubowski, Ann, Boulad, Farid, Perales, Miguel-Angel, Castro-Malaspina, Hugo, Small, Trudy N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: The American Society of Hematology 2006
Soggetti:
Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895570/
https://ncbi.nlm.nih.gov/pubmed/16763208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-04-006981
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi